The Asia Pacific Controlled Release Drug Delivery Market should witness market growth of 11.2% CAGR during the forecast period (2023-2030).
Communicable diseases, along with maternal, perinatal, and nutritional conditions, still accounted for close to half of deaths in low-income countries (LICs), with lower respiratory infections, diarrheal diseases, malaria, tuberculosis, and HIV/AIDS remaining in the top 10. A large portion of the burden of communicable diseases, particularly related to hepatitis B, neglected tropical diseases (NTDs), HIV, malaria, and tuberculosis (TB), was carried by LICs and LMICs.
The market's expansion is also anticipated to be fueled by the growing use of controlled release medication delivery systems in the treatment of chronic illnesses. In a July 2020 article titled "Drug Delivery System in the Treatment of Diabetes Mellitus," it was said that in order to effectively treat diabetes mellitus, proper delivery systems and comprehensive therapy techniques must be developed. According to the source, controlleddrug delivery devices have the potential to be helpful in many aspects of treating diabetes, including enhancing drug stability, breaking down various biologic obstacles in vivo to improve bioavailability, and serving as an intelligent automated system that imitates endogenous insulin delivery and lowers the risk of hypoglycemia.
Due to the region's expanding pharmaceutical industry, it has been receiving more attention worldwide. The pharmaceutical industries in China and India are rapidly expanding, helping the regional market. By 2024 and 2030, IBEF projects that the Indian pharmaceutical sector will be worth $65 billion and $130 billion. India currently has a $50 billion pharmaceutical sector. India exports pharmaceuticals to more than 200 nations, making it a significant global exporter. A mean industrial production index of 221.6 was recorded for 2021-2022 in the pharmaceutical, chemical, and botanical product industries.
In 2021-2022, $24.6 billion was exported in pharmaceutical and medical products. In addition, the most recent data from the National Health Accounts (NHA) 2022 report from Niti Aayog revealed that India's government health expenditure (GHE) amounted to 1.35% of the country's overall GDP in 2019-20. Hence,throughout the projection period, the market will expand quickly owing to increasing disease burden and healthcare expenditure.
The China market dominated the Asia Pacific Controlled Release Drug Delivery Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,072.5 million by 2030. The Japan market is exhibiting a CAGR of 10.5% during (2023-2030). Additionally, The India market would experience a CAGR of 11.9% during (2023-2030).
Based on Release Mechanism, the market is segmented into Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated, Polymer Based Systems and Micro Reservoir Partition Controlled Drug Delivery Systems. Based on Technology, the market is segmented into Targeted Delivery, Coacervation, Micro Encapsulation, Transdermal, Implants, Wurster Technique and Others. Based on Application, the market is segmented into Oral Controlled-drug delivery Systems, Metered Dose Inhalers, Injectable, Transdermal & Ocular Patches and Infusion Pumps & Drug Eluting Stents. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
Communicable diseases, along with maternal, perinatal, and nutritional conditions, still accounted for close to half of deaths in low-income countries (LICs), with lower respiratory infections, diarrheal diseases, malaria, tuberculosis, and HIV/AIDS remaining in the top 10. A large portion of the burden of communicable diseases, particularly related to hepatitis B, neglected tropical diseases (NTDs), HIV, malaria, and tuberculosis (TB), was carried by LICs and LMICs.
The market's expansion is also anticipated to be fueled by the growing use of controlled release medication delivery systems in the treatment of chronic illnesses. In a July 2020 article titled "Drug Delivery System in the Treatment of Diabetes Mellitus," it was said that in order to effectively treat diabetes mellitus, proper delivery systems and comprehensive therapy techniques must be developed. According to the source, controlleddrug delivery devices have the potential to be helpful in many aspects of treating diabetes, including enhancing drug stability, breaking down various biologic obstacles in vivo to improve bioavailability, and serving as an intelligent automated system that imitates endogenous insulin delivery and lowers the risk of hypoglycemia.
Due to the region's expanding pharmaceutical industry, it has been receiving more attention worldwide. The pharmaceutical industries in China and India are rapidly expanding, helping the regional market. By 2024 and 2030, IBEF projects that the Indian pharmaceutical sector will be worth $65 billion and $130 billion. India currently has a $50 billion pharmaceutical sector. India exports pharmaceuticals to more than 200 nations, making it a significant global exporter. A mean industrial production index of 221.6 was recorded for 2021-2022 in the pharmaceutical, chemical, and botanical product industries.
In 2021-2022, $24.6 billion was exported in pharmaceutical and medical products. In addition, the most recent data from the National Health Accounts (NHA) 2022 report from Niti Aayog revealed that India's government health expenditure (GHE) amounted to 1.35% of the country's overall GDP in 2019-20. Hence,throughout the projection period, the market will expand quickly owing to increasing disease burden and healthcare expenditure.
The China market dominated the Asia Pacific Controlled Release Drug Delivery Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,072.5 million by 2030. The Japan market is exhibiting a CAGR of 10.5% during (2023-2030). Additionally, The India market would experience a CAGR of 11.9% during (2023-2030).
Based on Release Mechanism, the market is segmented into Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated, Polymer Based Systems and Micro Reservoir Partition Controlled Drug Delivery Systems. Based on Technology, the market is segmented into Targeted Delivery, Coacervation, Micro Encapsulation, Transdermal, Implants, Wurster Technique and Others. Based on Application, the market is segmented into Oral Controlled-drug delivery Systems, Metered Dose Inhalers, Injectable, Transdermal & Ocular Patches and Infusion Pumps & Drug Eluting Stents. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
Scope of the Study
By Release Mechanism
- Feedback Regulated Drug Delivery Systems
- Activation-modulated Drug Delivery Systems
- Chemically Activated
- Polymer Based Systems
- Micro Reservoir Partition Controlled Drug Delivery Systems
By Technology
- Targeted Delivery
- Coacervation
- Micro Encapsulation
- Transdermal
- Implants
- Wurster Technique
- Others
By Application
- Oral Controlled-drug delivery Systems
- Metered Dose Inhalers
- Injectable
- Transdermal & Ocular Patches
- Infusion Pumps & Drug Eluting Stents
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Controlled Release Drug Delivery Market by Release Mechanism
Chapter 6. Asia Pacific Controlled Release Drug Delivery Market by Technology
Chapter 7. Asia Pacific Controlled Release Drug Delivery Market by Application
Chapter 8. Asia Pacific Controlled Release Drug Delivery Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Merck & Co., Inc.
- Alkermes PLC
- Pfizer, Inc.
- Assertio Holdings, Inc. (Assertio Therapeutics, Inc.)
- Lonza Group AG (Capsugel)
- Colorcon, Inc. (BPSI Holdings LLC.)
- Corium, LLC (Gurnet Point Capital)
- Adare Pharma Solutions
- Coating Place, Inc.
Methodology
LOADING...
